(TheNewswire)
Calgary, Alberta – TheNewswire - May 24, 2022 - Ocumetics Technology Corp. (“ Ocumetics ” or the“ Company ”) ( TSXV:OTC) is pleased to providean update on preclinical bench test results of its lens technologies.
In recent bench tests conducted by Ocumetics, theCompany’s latest accommodating lens design consistently achieved 12diopters of accommodation, which allows the eye to focus on objectsless than 4 inches away.
“These remarkable results are the culmination of over15 years of research by our founder and Chief Scientific Officer, Dr.Garth Webb,” said Dr. Mark Lee, CEO of Ocumetics. “Although thebench results need to be verified in clinical trials, I believe ourproducts have the potential to be transformative in the eye careindustry,” adds Dr. Lee.
“The lens was designed to produce 12 diopters ofaccommodation, and it is gratifying to see the prototypes deliveringthose results in bench tests,” said Dr. Garth Webb, the inventorOcumetics’ lens technologies. “Moreover, the clarity of the imagesproduced by the lens itself is everything we had hoped for,” addsDr. Webb.
“ If Ocumetics’ lenstechnologies can achieve only half of the bench test accommodationamplitude in human trials, we will be able to offer older adults theopportunity to have near vision like they had when they wereteenagers ,” said Dr. Doyle Stulting,Ocumetics’ Chief Medical Officer.
Preclinical studies for Ocumetics’ accommodating lenstechnology are scheduled to be completed in Q3 2022. The firstproof-of-concept human studies are expected to begin shortlythereafter, in Q4 2022. Full clinical trials are expected to begin in2023.
About Ocumetics
Ocumetics Technology Corp. ( TSXV:“OTC”) is a Canadian researchand product development company that specializes in adaptive lensdesigns. Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry. Ocumetics hasdeveloped an expandable intraocular lens that fits within the naturallens compartment of the eye potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dr. Mark Lee
President and CEO
(604) 832-6052
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but arenot limited to, statements with respect to the commencement, timingand scope of the clinical trial program outlined above and that itwill be conducted as expected. Forward-looking statements arenecessarily based upon a number of estimates and assumptions that,while considered reasonable, are subject to known and unknown risks,uncertainties, and other factors which may cause the actual resultsand future events to differ materially from those expressed or impliedby such forward-looking statements. Such factors include but are notlimited to: operational matters, historical trends, current conditionsand expected future developments, access to financing as well as otherconsiderations that are believed to be appropriate in thecircumstances. There can be no assurance that such statements willprove to be accurate, as actual results and future events could differmaterially from those anticipated in such statements. Accordingly,readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update orrevise any forward-looking statements, whether as a result of newinformation, future events or otherwise, except as required bylaw.
Copyright (c) 2022 TheNewswire - All rights reserved.